Regulation of Transgene Expression by the Natural Sweetener Xylose.
Ontology highlight
ABSTRACT: Next-generation gene and engineered-cell therapies benefit from incorporating synthetic gene networks that can precisely regulate the therapeutic output in response to externally administered signal inputs that are safe, readily bioavailable and pleasant to take. To enable such therapeutic control, a mammalian gene switch is designed to be responsive to the natural sweetener xylose and its functionality is assessed in mouse studies. The gene switch consists of the bacterial transcription regulator XylR fused to a mammalian transactivator, which binds to an optimized promoter in the presence of xylose, thereby allowing dose-dependent transgene expression. The sensitivity of SWEET (sweetener-inducible expression of transgene) is improved by coexpressing a xylose transporter. Mice implanted w
SUBMITTER: Galvan S
PROVIDER: S-EPMC9731693 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA